qXR-CTR vs AVIEW
AI Verdict
Choose qXR-CTR if…
Choose qXR-CTR if your primary need is rapid, automated assessment of heart size and potential heart failure risk directly from chest X-ray images. This tool is ideal for streamlining initial cardiac screening workflows where quick, AI-powered cardiothoracic ratio measurements are crucial.
View qXR-CTR →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for detailed analysis of CT scans, particularly for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification. This solution is best suited for advanced radiology workflows demanding features like lung nodule characterization, emphysema quantification, and detailed coronary artery calcium scoring.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | qXR-CTR | AVIEW |
|---|---|---|
| Pricing | Unknown | Subscription; one-off payment |
| Deployment | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWTool B (AVIEW) offers comprehensive workflow automation, integration with PACS/RIS/CIS, 3D visualizations, and features like follow-up registration and nodule matching, suggesting a highly integrated and streamlined experience for complex CT workflows. While Tool A (qXR-CTR) provides rapid, focused analysis and mobile access for X-rays, Tool B's broader feature set for multi-disease analysis and workflow efficiency points to a more comprehensive user experience for radiologists.
Clinical Value
AVIEWTool B (AVIEW) demonstrates superior clinical value by offering comprehensive solutions for multiple high-fatality diseases, including lung cancer, COPD, coronary artery calcification, and Interstitial Lung Disease (ILD) pattern analysis, based on detailed CT scans. In contrast, Tool A (qXR-CTR) focuses on a specific, albeit important, measurement of cardiothoracic ratio for heart failure risk from chest X-rays. Tool B's broader diagnostic scope and advanced quantitative analysis across multiple pathologies provide more extensive clinical utility.
Pricing & Value
AVIEWTool B (AVIEW) offers more transparency regarding its pricing model, stating it provides both subscription and one-off payment options based on the number of installations or users. Tool A (qXR-CTR) does not publicly disclose any pricing information, requiring direct contact for details. This greater clarity from Tool B allows potential customers to better understand the cost structure.
Enterprise Readiness
TieBoth tools exhibit strong enterprise readiness with FDA clearance, HIPAA compliance, and flexible deployment options including cloud, on-premise, and hybrid solutions. Tool A explicitly mentions a Business Associate Agreement (BAA), while Tool B highlights GDPR compliance, advanced virtualization options (Docker), and proven adoption in national lung cancer screening programs. Both demonstrate robust capabilities for integration into existing healthcare IT environments.
Innovation
AVIEWTool B (AVIEW) shows greater innovation through its comprehensive, integrated platform approach that addresses multiple complex diseases (lung cancer, COPD, CAC, ILD) with advanced quantitative analysis, 3D visualizations, and longitudinal follow-up capabilities. It represents a shift towards a unified diagnostic ecosystem. While Tool A (qXR-CTR) automates a specific measurement, Tool B's breadth, depth, and integrated workflow automation signify a more substantial innovative advancement in medical imaging AI.
Support & Docs
TieBoth companies provide documentation and resources to support their products. Qure.ai offers a user manual for its app, while Coreline Soft provides a knowledge base, case studies, and technical catalogs. Without specific comparative information on the quality, responsiveness, or breadth of their support services, it is not possible to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | qXR-CTR | AVIEW |
|---|---|---|
| Name | qXR-CTR | AVIEW |
| Company | Qure.ai Technologies | Coreline Soft Co. |
| Primary Function | Automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. | Offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. |
| Tagline | AI-powered Chest X-ray Solution for Automated Cardiothoracic Ratio Assessment. | AI-Driven Diagnostic Solutions for Medical Imaging |
| Target Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Key AI Capabilities | Automated measurement of cardiothoracic ratio (CTR) from chest X-ray images. | AI-powered lung nodule detection and characterization, Emphysema quantification, Coronary artery calcium (CAC) scoring, Automated segmentation of lung lobes, airways, vessels, and coronary arteries, 3D visualizations, Workflow automation, Follow-up registration and nodule matching, Interstitial Lung Disease (ILD) pattern analysis. |
Videos
Demos, reviews, and walkthroughs featuring qXR-CTR and AVIEW.